Literature DB >> 32405161

D-dimer in patients infected with COVID-19 and suspected pulmonary embolism.

Ignasi Garcia-Olivé1,2,3, Helena Sintes1,4, Joaquim Radua5,6,7,8, Jorge Abad Capa1,2,3,4, Antoni Rosell1,2,3,4.   

Abstract

Objective: To analyze the risk factors for pulmonary embolism (PE) in patients infected with COVID-19.
Methods: We conducted an observational, retrospective study. Patients with severe infection with COVID-19 and suspected PE were included.
Results: Patients with higher levels of D-dimer and those requiring intubation were at a higher risk of developing PE. Higher D-dimer levels were associated with a greater probability of PE 3, 6, 9 and 12 days after determining D-dimer levels with an OR of 1.7, 2.0, 2.4 and 2.4, respectively.
Conclusion: In conclusion, patients infected with COVID-19 requiring OTI with higher levels of D-dimer have an increased risk of developing PE.
© 2020 Elsevier Ltd. All rights reserved.

Keywords:  COVID-19; D-dimer; Pulmonary embolism

Year:  2020        PMID: 32405161      PMCID: PMC7219417          DOI: 10.1016/j.rmed.2020.106023

Source DB:  PubMed          Journal:  Respir Med        ISSN: 0954-6111            Impact factor:   3.415


  9 in total

1.  Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy.

Authors:  Ning Tang; Huan Bai; Xing Chen; Jiale Gong; Dengju Li; Ziyong Sun
Journal:  J Thromb Haemost       Date:  2020-04-27       Impact factor: 5.824

2.  Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia.

Authors:  Ning Tang; Dengju Li; Xiong Wang; Ziyong Sun
Journal:  J Thromb Haemost       Date:  2020-03-13       Impact factor: 5.824

3.  Prevalence of venous thromboembolism in patients with severe novel coronavirus pneumonia.

Authors:  Songping Cui; Shuo Chen; Xiunan Li; Shi Liu; Feng Wang
Journal:  J Thromb Haemost       Date:  2020-05-06       Impact factor: 5.824

4.  Hematologic parameters in patients with COVID-19 infection.

Authors:  Bingwen Eugene Fan; Vanessa Cui Lian Chong; Stephrene Seok Wei Chan; Gek Hsiang Lim; Kian Guan Eric Lim; Guat Bee Tan; Sharavan Sadasiv Mucheli; Ponnudurai Kuperan; Kiat Hoe Ong
Journal:  Am J Hematol       Date:  2020-03-19       Impact factor: 10.047

5.  Diagnostic utility of clinical laboratory data determinations for patients with the severe COVID-19.

Authors:  Yong Gao; Tuantuan Li; Mingfeng Han; Xiuyong Li; Dong Wu; Yuanhong Xu; Yulin Zhu; Yan Liu; Xiaowu Wang; Linding Wang
Journal:  J Med Virol       Date:  2020-04-10       Impact factor: 2.327

6.  Acute pulmonary embolism and COVID-19 pneumonia: a random association?

Authors:  Gian Battista Danzi; Marco Loffi; Gianluca Galeazzi; Elisa Gherbesi
Journal:  Eur Heart J       Date:  2020-05-14       Impact factor: 29.983

7.  Incidence of thrombotic complications in critically ill ICU patients with COVID-19.

Authors:  F A Klok; M J H A Kruip; N J M van der Meer; M S Arbous; D A M P J Gommers; K M Kant; F H J Kaptein; J van Paassen; M A M Stals; M V Huisman; H Endeman
Journal:  Thromb Res       Date:  2020-04-10       Impact factor: 3.944

Review 8.  Cardiovascular Considerations for Patients, Health Care Workers, and Health Systems During the COVID-19 Pandemic.

Authors:  Elissa Driggin; Mahesh V Madhavan; Behnood Bikdeli; Taylor Chuich; Justin Laracy; Giuseppe Biondi-Zoccai; Tyler S Brown; Caroline Der Nigoghossian; David A Zidar; Jennifer Haythe; Daniel Brodie; Joshua A Beckman; Ajay J Kirtane; Gregg W Stone; Harlan M Krumholz; Sahil A Parikh
Journal:  J Am Coll Cardiol       Date:  2020-03-19       Impact factor: 24.094

9.  Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study.

Authors:  Fei Zhou; Ting Yu; Ronghui Du; Guohui Fan; Ying Liu; Zhibo Liu; Jie Xiang; Yeming Wang; Bin Song; Xiaoying Gu; Lulu Guan; Yuan Wei; Hui Li; Xudong Wu; Jiuyang Xu; Shengjin Tu; Yi Zhang; Hua Chen; Bin Cao
Journal:  Lancet       Date:  2020-03-11       Impact factor: 79.321

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.